Together, these results show that FAAH is not just a marker, but also a driver of a less aggressive, luminal-like tumor phenotype, and therefore it offers the potential to be studied as a candidate for differentiation therapy in patients with basal-like BC. The gene discussed is FAAH; the disease is neoplasm.